# IXHL catalysts: Incannex Healthcare Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ixhl/catalysts

> Incannex Healthcare Inc. (IXHL) has 2 upcoming catalysts. The next is the ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide primary completion, April 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Incannex Healthcare Inc. |
| Ticker | IXHL (Nasdaq) |
| SEC CIK | 1873875 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ixhl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide topline data readout](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | completed, positive | "In January 2024, we released positive topline results from a completed" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1873875/000121390025013783/ea0230488-10q_incannex.htm)) |
| Nov 2024 | [IHL-675A trial start](https://sec-api.dev/pdufa/ihl-675a) | IXHL |  | completed | "We initiated an Australian Phase 2 trial investigating IHL-675A in rheumatoid arthritis patients; however, in November 2024, we paused patient recruitment due to slower than anticipated enrollment and subsequently terminated the trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1873875/000162828026063506/ixhl-20260630.htm)) |
| 1H 2025 | [Incannex Healthcare Inc. topline data readout](https://sec-api.dev/companies/ixhl/catalysts) | IXHL |  | scheduled | "A topline readout from the U.S. Phase 2 portion is anticipated in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390025013787/ea023115301ex99-1_incannex.htm)) |
| January 23, 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide topline data readout](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | completed, positive | "2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced positive topline results from a completed pharmacokinetics (PK) and safety study of IHL-42X, a novel, oral fixed-dose combination of acetazolamide and dronabinol for the treatment of Obstructive Sleep Apnea (OSA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390025005700/ea022831301ex99-1_incannex.htm)) |
| May 20, 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide primary completion](https://sec-api.dev/pdufa/ihl-42x) | IXHL | Obstructive Sleep Apnea | completed | "NCT06146101 (RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-05-20 (ACTUAL); Lead Sponsor Incannex Healthcare Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06146101)) |
| Jul 2025 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide topline data readout](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | scheduled | "This eliminates a significant source of dilution and leaves Incannex with a clean capital structure ahead of key milestones, including the upcoming topline data readout from our Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390025053588/ea024539601ex99-1_incannex.htm)) |
| Aug 2025 | [PSX-001 topline data readout](https://sec-api.dev/pdufa/psx-001) | IXHL |  | completed, positive | "In August 2025, the Company reported positive topline results from the completed 73-subject PsiGAD1 Phase 2 study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026098213/ea030478201ex99-1.htm)) |
| July 23, 2026 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide trial start](https://sec-api.dev/pdufa/ihl-42x) | IXHL | obstructive sleep apnea | completed | "Australia and NEW YORK, 23 July, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications, is pleased to announce that participant screening has commenced in the Company's DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea ("OSA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea029867401ex99-1.htm)) |
| August 25, 2026 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide trial start](https://sec-api.dev/pdufa/ihl-42x) | IXHL |  | completed | "Incannex Announces First Patient Dosed in DReAMzz" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea030314001ex99-1.htm)) |
| April 2027 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide primary completion](https://sec-api.dev/pdufa/ihl-42x) | IXHL | Obstructive Sleep Apnea (OSA) | scheduled | "NCT07635563 (DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Incannex Healthcare Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07635563)) |
| Apr to Jul 2027 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide topline data readout](https://sec-api.dev/pdufa/ihl-42x) | IXHL | Obstructive Sleep Apnea (OSA) | scheduled | "NCT07635563 (DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Incannex Healthcare Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07635563)) |

## Drugs

- [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide](https://sec-api.dev/pdufa/ihl-42x): obstructive sleep apnea, Obstructive Sleep Apnea (OSA)
- [IHL-675A](https://sec-api.dev/pdufa/ihl-675a): 
- [PSX-001](https://sec-api.dev/pdufa/psx-001): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ixhl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IXHL catalysts: Incannex Healthcare Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ixhl/catalysts

```bibtex
@misc{secapidev_companies_ixhl_catalysts_20261116,
  title        = {IXHL catalysts: Incannex Healthcare Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ixhl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ixhl_catalysts_20261116","title":"IXHL catalysts: Incannex Healthcare Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ixhl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
